Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug

Summary: The highly lethal brain cancer glioblastoma (GBM) poses a daunting challenge because the blood-brain barrier renders potentially druggable amplified or mutated oncoproteins relatively inaccessible. Here, we identify sphingomyelin phosphodiesterase 1 (SMPD1), an enzyme that regulates the con...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Junfeng Bi, Atif Khan, Jun Tang, Aaron M. Armando, Sihan Wu, Wei Zhang, Ryan C. Gimple, Alex Reed, Hui Jing, Tomoyuki Koga, Ivy Tsz-Lo Wong, Yuchao Gu, Shunichiro Miki, Huijun Yang, Briana Prager, Ellis J. Curtis, Derek A. Wainwright, Frank B. Furnari, Jeremy N. Rich, Timothy F. Cloughesy, Harley I. Kornblum, Oswald Quehenberger, Andrey Rzhetsky, Benjamin F. Cravatt, Paul S. Mischel
Format:	article
Langue:	EN
Publié:	Elsevier 2021
Sujets:	glioblastoma sphingolipid metabolism SMPD1 fluoxetine Membrane lipids EGFR signaling Biology (General) QH301-705.5
Accès en ligne:	https://doaj.org/article/8516b7196aa84c49af33aefb9f94a103
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug

Documents similaires